Clinical Trials Logo

Impetigo clinical trials

View clinical trials related to Impetigo.

Filter by:

NCT ID: NCT01153828 Completed - Impetigo Clinical Trials

EU PV for Retapamulin-Prescribing

Start date: November 2008
Phase: N/A
Study type: Observational

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.

NCT ID: NCT01126268 Completed - Impetigo Clinical Trials

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.

NCT ID: NCT00884728 Completed - Scabies Clinical Trials

Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory

EAHSP
Start date: September 2004
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a coordinated regional approach to healthy skin programs in six remote Aboriginal communities can demonstrate, not only a reduction in the burden of scabies and streptococcal skin sores, but also broad health benefits, including primary prevention of some chronic diseases that occur at particularly high rates in Australian Aboriginal communities. The primary objectives of the Program are: - Demonstrate a reduction in scabies and skin sores on a regional basis - Demonstrate the broader public health effects of Healthy Skin Programs, particularly those relating to chronic diseases such as rheumatic fever and renal diseases - Build on the existing Indigenous capacity by assisting in the development of new knowledge and skills to improve the health and well being of Indigenous communities - Establish the feasibility of incorporating Healthy Skin Programs into existing health service delivery

NCT ID: NCT00852540 Completed - Impetigo Clinical Trials

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.

NCT ID: NCT00758862 Completed - Impetigo Clinical Trials

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

Start date: December 2008
Phase: Phase 2
Study type: Interventional

A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.

NCT ID: NCT00626795 Completed - Impetigo Clinical Trials

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Start date: February 2008
Phase: Phase 2
Study type: Interventional

An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.

NCT ID: NCT00133874 Completed - Clinical trials for Skin Infections, Bacterial

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

Start date: April 2005
Phase: Phase 3
Study type: Interventional

The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

NCT ID: NCT00133848 Completed - Impetigo Clinical Trials

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Start date: April 2005
Phase: Phase 3
Study type: Interventional

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.